ReviewJournal of hematology & oncology2013
Novel agents and biomarkers for acute lymphoid leukemia.
Review in Journal of hematology & oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Healthcare utilization and cost of cancer-related care prior to allogeneic hematopoietic cell transplantation for hematologic malignancies in the US: a retrospective real-world analysis.BMC health services research · 2021Article
- The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively.Cancer medicine · 2021Review
- MYCN is a novel oncogenic target in adult B-ALL that activates the Wnt/β-catenin pathway by suppressing DKK3.Journal of cellular and molecular medicine · 2018Article
- Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells.Journal of hematology & oncology · 2015Article
- Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.Journal of hematology & oncology · 2015Review
- Establishment and genetic characterization of a novel mixed-phenotype acute leukemia cell line with EP300-ZNF384 fusion.Journal of hematology & oncology · 2015Article
- Favorable outcome of haploidentical hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a multicenter study in Southwest China.Journal of hematology & oncology · 2015Article
- Galectin-3 mediates bone marrow microenvironment-induced drug resistance in acute leukemia cells via Wnt/β-catenin signaling pathway.Journal of hematology & oncology · 2015Article
- Molecular targeting of the oncoprotein PLK1 in pediatric acute myeloid leukemia: RO3280, a novel PLK1 inhibitor, induces apoptosis in leukemia cells.International journal of molecular sciences · 2015Article
- Overexpression of MALT1-A20-NF-κB in adult B-cell acute lymphoblastic leukemia.Cancer cell international · 2015Article
- Haploidentical hematopoietic transplantation without T-cell depletion: current status and future perspectives.Stem cell investigation · 2015Review
- High rates of submicroscopic aberrations in karyotypically normal acute lymphoblastic leukemia.Molecular cytogenetics · 2015Article
- Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG.Experimental hematology & oncology · 2015Article
- Characteristics of CARMA1-BCL10-MALT1-A20-NF-κB expression in T cell-acute lymphocytic leukemia.European journal of medical research · 2014Article
- Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.Journal of hematology & oncology · 2014Review
- Practice gaps and barriers to optimal care of hematologic malignancies in the United States.The Journal of community and supportive oncology · 2014Article
- Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock.Frontiers of medicine · 2014Article
- Ibrutinib for B cell malignancies.Experimental hematology & oncology · 2014Article
- Challenges and opportunities for cancer vaccines in the current NSCLC clinical scenario.Current topics in medicinal chemistry · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New genetic markers for adult acute lymphoblastic leukemia (ALL) have been found to have prognostic impact, such as the lymphoid transcription factor gene IKZF1 alterations, which are associated with a high rate of leukemic relapse in B-ALL. Although complete remission rates by induction chemotherapy in ALL are now high, the long-term survival is still disappointing. Improvements in the survival outcome of ALL have been observed in young adults as a result of the use of pediatric inspired regimens and the broadening of the number of patients who are eligible for allogeneic SCT. Development of new and less toxic agents also provide promise to improve the outcome in adult ALL, such as tyrosine kinase inhibitors in Ph-positive ALL, rituximab in CD20-positive disease, blinatumomab in precursor B-ALL and nelarabine in T-lineage ALL. Challenges for the future are to implement genomic profiling into the clinical setting to guide risk stratification and providing novel targets for tailored therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.